Form 8-K - Current report:
SEC Accession No. 0001493152-22-002162
Filing Date
2022-01-25
Accepted
2022-01-25 06:30:17
Documents
14
Period of Report
2022-01-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 62909
2 ex99-1.htm EX-99.1 47036
3 ex99-1_001.jpg GRAPHIC 35144
  Complete submission text file 0001493152-22-002162.txt   351238

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mtnb-20220125.xsd EX-101.SCH 3057
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mtnb-20220125_lab.xml EX-101.LAB 35156
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mtnb-20220125_pre.xml EX-101.PRE 23045
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3762
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 22551067
SIC: 2834 Pharmaceutical Preparations